• Caithness Energy in an agreement to sell its Moxie Freedom Energy Center in Pennsylvania and Caithness Energy and BlackRock’s Guernsey Power Station in Ohio to Talen Energy Corporation ($3.8 billion)
• Allovue, Inc. in connection with its sale to PowerSchool Promachos Holding, Inc. d/b/a PowerSchool (NYSE: PWSC) ($42 million)
• Alvotech in connection with its agreement to merge with Oaktree Acquisition Corp. II (NYSE: OACB) ($2.25 billion)
• Ascend Advanced Therapies Limited in connection with its acquisition of Advanced BioScience Laboratories, Inc. (ABL)
• Athenex, Inc. (NASDAQ: ATNX) in connection with its acquisition of Kuur Therapeutics, Inc. ($185 million)
• Bavarian Nordic A/S (OMX: BAVA) in connection with its acquisition of Emergent BioSolutions, Inc.’s (NYSE: EBS) travel vaccines portfolio, including VIVOTIF®, VAXCHORA® and a development-stage chikungunya vaccine candidate (up to $380 million)
• biote Corp. in connection with its agreement to merge Haymaker Acquisition Corp. III (NASDAQ: HYAC) ($737 million)
• Causal, Inc. in connection with its sale to LucaNet Holding GmbH
• Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) in connection with its acquisition of certain assets from Eisai Co., Ltd., including the U.S. rights for FYCOMPA® (perampanel) CIII and an exclusive option period to acquire a rare epilepsy asset (up to $185 million + royalties)
• Evox Therapeutics Ltd. in connection with its acquisition of certain assets sold out of Codiak BioSciences, Inc.’s bankruptcy proceedings, including Codiak’s engEx-AAV™ technology platform
• MacroGenics, Inc. (NASDAQ: MGNX) in connection with its sale of certain assets, including the global rights to MARGENZA® (margetuximab-cmkb TerSera Therapeutics LLC (up to $75 million)
• Malk Sustainability Partners, Inc. in connection with its sale to SLR International Corp.
• Oculis Holdings AG in connection with its agreement to merge with European Biotech Acquisition Corp. (NASDAQ: EBAC) ($248 million)
• Rooam, Inc. in connection with its sale to American Express Travel Related Services Company, Inc. (NYSE: AXP)
• SEDNA Communications Ltd. in connection with its acquisition of certain assets from Boxton, Inc., including its email automation solution, Shelly
• A group of investors led by Stride Capital in connection with the sale of Hofy LTD. to Deel, Inc.
• Toluna Holdings Limited in connection with its acquisition of Brainyak, Inc. d/b/a Gutcheck ($45 million)
• ZOLL Medical Corporation in connection with its acquisition of Itamar Medical Ltd. (NASDAQ and TASE: ITMR) ($538 million)
• RedHill Biopharma, Inc. (NASDAQ: RDHL) in connection with its acquisition of certain assets from AstraZeneca AB (NYSE: AZN), including a sublicense to the global rights to Movantik® (naloxegol) ($67.5 million)
• Becle S.A.B. de C.V. d/b/a Jose Cuervo (BMV:CUERVO) in connection with its acquisition of the Canadian whisky brand Pendleton from Hood River Distillers, Inc. ($208 million)
• Linde AG (FWB: LIN) in connection with its “merger of equals” with Praxair, Inc. (NYSE: LIN) ($90 billion)
• Rock-Tenn Company in connection with its combination with MeadWestvaco Corporation to create WestRock Company (NYSE: WRK) ($16 billion)
• The Spectranetics Corporation (NASDAQ: SPNC) in connection with its sale to Royal Philips (NYSE: PHG and AEX: PHIA) (€1.9 billion)

Matters may have been completed before joining Paul Hastings.

• Co-Author, "Beyond Borders: A Guide for Navigating the European Regulatory Landscape," Cooley M&A, June 10, 2024
• Co-Author, "Cooley’s 2023 Cross-Border M&A Year in Review: Navigating Choppy Waters Into a More Buoyant 2024," Cooley M&A, January 25, 2024